ORPHA:69078
Liposarcoma
Publications
24,023
Trials
134
Interventional, condition-specific
Researchers
1,319
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Liposarcoma (LS), a type of soft tissue sarcoma, describes a group of lipomatous tumors of varying severity ranging from slow-growing to aggressive and metastatic. Liposarcomas are most often located in the lower extremities or retroperitoneum, but they can also occur in the upper extremities, neck, peritoneal cavity, spermatic cord, breast, vulva and axilla.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005060
- MeSH:D008080
- UMLS:C0023827
- NCIT:C3194
Additional Mondo synonyms (4)
lip sarcoma · liposarcoma · liposarcoma, malignant · sarcoma of lip
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
24,023 matched papers (13,158 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
134 matched on ClinicalTrials.gov (31 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
24,023
24,023 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
24,023 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
13,158 in the last 10 years · low confidence
Phrase hits: 24,023 · MeSH hits: 672
Who's working on it?
1,319
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li W5 papers · 2026
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China. Electronic address: liwenjie@pkuih.edu.cn.
Papers in Europe PMC - 02Li Y5 papers · 2026
Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. zhaojc3@163.com.
Papers in Europe PMC - 03Wang J5 papers · 2026
Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. zhaojc3@163.com.
Papers in Europe PMC - 04Gronchi A4 papers · 2026
Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 05
- 06Tseng WW4 papers · 2026
Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA. wtseng@coh.org.
Papers in Europe PMC - 07Vanzulli A4 papers · 2026
Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 08Yang Z4 papers · 2026
Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471003, China.
Papers in Europe PMC - 09Allajbej A3 papers · 2026
Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 10Baia M3 papers · 2026
Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
134
interventional trials for this specific condition
134 interventional trials matched this specific condition name; 31 currently recruiting in our sample.
Data as of 27 July 2026
134 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.8th percentile).
low confidence · 98.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
134 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name + MeSH
- NCT06957431·RECRUITING·Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Conditions: Advanced Leiomyosarcoma · Adipocytic Sarcoma · Advanced Liposarcoma·Matched via name + MeSH
- NCT07224568·NOT YET RECRUITING·Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Conditions: Solid Tumor (Excluding CNS) · Hepatocellular Carcinoma · Liver Cell Carcinoma · Liposarcoma·Matched via name + MeSH
- NCT06389799·RECRUITING·A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Conditions: Dedifferentiated Liposarcoma·Matched via name + MeSH
- NCT05492682·RECRUITING·START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Conditions: Melanoma (Skin) · Triple-Negative Breast Cancer · Non-Small Cell Lung Cancer · Synovial Sarcoma·Matched via name + MeSH
- NCT05711615·RECRUITING·Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Leiomyosarcoma · Metastatic Myxofibrosarcoma · Metastatic Sarcoma·Matched via name + MeSH
- NCT04785196·RECRUITING·APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Conditions: Liposarcoma · Advanced Solid Tumor·Matched via name + MeSH
- NCT07686367·NOT YET RECRUITING·Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Conditions: Metastatic Myxoid Liposarcoma · Metastatic Synovial Sarcoma · Unresectable Myxoid Liposarcoma · Unresectable Synovial Sarcoma·Matched via name + MeSH
- NCT07169344·RECRUITING·Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma (Excluding GIST) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name + MeSH
- NCT06422806·RECRUITING·Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Undifferentiated Pleomorphic Sarcoma · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8·Matched via name + MeSH
- NCT06025747·RECRUITING·A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Conditions: Retroperitoneal Sarcoma · Liposarcoma · Dedifferentiated Liposarcoma·Matched via name + MeSH
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name + MeSH
- NCT04224064·RECRUITING·Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Conditions: Liposarcoma · Atypical Lipomatous Tumor·Matched via name + MeSH
- NCT07173972·RECRUITING·Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Conditions: Soft Tissue Sarcoma (STS) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name + MeSH
- NCT06843967·RECRUITING·A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Conditions: Well Differentiated Liposarcoma · Dedifferentiated Liposarcoma · Liposarcoma · Myxoid Liposarcoma·Matched via name + MeSH
Observational and natural-history studies
14 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04699292·RECRUITING·International Prospective Registry on Local Treatment Approaches in MLS
Conditions: Myxoid Liposarcoma·Matched via name + MeSH
- NCT07432932·RECRUITING·Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Conditions: Sarcoma · Sarcoma, Leiomyo-, Adult · Sarcoma, Synovial, Adult · Soft Tissue Sarcoma (STS)·Matched via name + MeSH
- NCT06039046·NOT YET RECRUITING·Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Conditions: Liposarcoma·Matched via name + MeSH
- NCT07377747·RECRUITING·Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Conditions: Retroperitoneal Liposarcoma·Matched via name + MeSH
- NCT06436846·RECRUITING·Genomic Risk in Retroperitoneal Sarcoma
Conditions: Retroperitoneal Liposarcoma · Soft Tissue Sarcoma·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Liposarcoma" OR "lip sarcoma" OR "liposarcoma, malignant" OR "sarcoma of lip" OR "sarcoma of the lip"
MeSH descriptor terms unioned into the query: Liposarcoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Liposarcoma" OR "lip sarcoma" OR "liposarcoma, malignant" OR "sarcoma of lip" OR "sarcoma of the lip"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 134 interventional · 14 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (24023) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T01:27:36.058Z
